Lactiplantibacillus plantarum (Lactobacillaceae): The Versatile Probiotic Powerhouse for Gut, Metabolic, and Beyond

Lactiplantibacillus plantarum, formerly known as Lactobacillus plantarum, is a premier next-generation probiotic and one of the most versatile and well-studied beneficial bacteria in the human microbiome. This Gram-positive, facultatively anaerobic bacterium belongs to the family Lactobacillaceae and is distinguished by exceptional adaptability, enabling it to thrive in diverse environments ranging from the human gastrointestinal tract to fermented foods. Its remarkable metabolic flexibility and potent antimicrobial arsenal position it as a cornerstone of probiotic therapy and a key modulator of host health across multiple body systems.

Research from 2025 and 2026 has catapulted L. plantarum into the forefront of microbiome-based therapeutics, with groundbreaking applications spanning diabetic macular edema, hepatic encephalopathy, atopic dermatitis, neuroinflammation, and type 2 diabetes. Its unique ability to produce a diverse array of bacteriocins (plantaricins) provides natural antimicrobial defense against foodborne pathogens including Listeria monocytogenes. Cutting-edge synthetic biology has enabled the engineering of L. plantarum strains that simultaneously assimilate ammonia, produce branched-chain amino acids, and metabolize glutamine, offering transformative potential for treating complex metabolic disorders of the gut-liver-brain axis. The emergence of paraprobiotic (heat-killed) formulations has expanded its applications to immune-mediated conditions like atopic dermatitis, while ongoing clinical trials are investigating its role in optimizing iron status during pregnancy and reducing anti-VEGF injections in diabetic macular edema patients. Its recognition as a Generally Recognized as Safe (GRAS) organism and its long history of safe use in fermented foods make it an ideal chassis for engineered live biotherapeutic products.

---

Where It Is Found

Lactiplantibacillus plantarum is ubiquitously distributed across natural environments, the human body, and fermented food products, reflecting its extraordinary ecological adaptability.

Human Gastrointestinal Tract

L. plantarum colonizes the human gut from early life, persisting as a transient or resident member of the microbiota depending on dietary intake and individual factors. Unlike obligate anaerobes, its facultative anaerobic nature allows it to thrive in various oxygen gradients along the intestinal tract, from the more oxygenated small intestine to the anaerobic colon.

Fermented Foods

This species is a dominant microorganism in a wide array of traditional fermented foods worldwide

· Dairy products including cheese, yogurt, and fermented milk

· Vegetable ferments such as sauerkraut, kimchi, pickles, and olives

· Cereal-based ferments including sourdough and ogi

· Meat products such as fermented sausages

· Plant-based ferments from regions including Chinese Sichuan pickles, where strains like RX-8 have been isolated

Natural Environments

L. plantarum is found in plant materials, silage, and environmental samples, reflecting its adaptation to plant-associated niches that likely serve as routes of entry to the human digestive system.

Animal Reservoirs

The bacterium is present in the gastrointestinal tracts of various animals including mice, rats, and livestock, providing valuable models for studying its function and therapeutic potential.

Mucosal Surfaces

Beyond the gut, L. plantarum can colonize other mucosal surfaces including the oral cavity and vaginal tract, though its primary niche remains the intestinal ecosystem.

External Sources

Unlike strictly host-adapted commensals, L. plantarum is readily acquired through dietary consumption of fermented foods, making it a culturable and accessible probiotic for supplementation.

---

1. Taxonomic Insights

Scientific Name: Lactiplantibacillus plantarum (formerly Lactobacillus plantarum) (Orla-Jensen 1919) Zheng et al. 2020

Family: Lactobacillaceae

Phylum: Bacillota (formerly Firmicutes)

Taxonomic Note

The species was originally described by Orla-Jensen in 1919 as Lactobacillus plantarum. In 2020, a comprehensive reclassification of the genus Lactobacillus resulted in the transfer of L. plantarum to the newly created genus Lactiplantibacillus, along with other former lactobacilli including L. pentosus and L. paraplantarum. This reclassification was based on whole-genome phylogenomic analyses that revealed distinct clades within the former Lactobacillus genus. Despite the taxonomic update, the common name Lactobacillus plantarum remains widely used in clinical and commercial contexts. The species is remarkably heterogeneous, with genomically distinct strains adapted to different ecological niches, ranging from plant-associated to human-adapted lineages.

Genomic Insights

The genome of L. plantarum is notably larger than many other lactic acid bacteria, typically ranging from 3.0 to 3.5 Mbp with a G+C content of approximately 44 to 45 percent. This expanded genome encodes an extensive repertoire of carbohydrate-active enzymes and sugar transport systems, enabling utilization of over 50 different carbohydrates. The genome of strain Z-5, isolated from traditional Chinese fermented foods, is 3.38 Mbp and contains a complete plantaricin biosynthesis gene cluster encoding Pln A, Pln E, and Pln F.

Key genomic features include

· Multiplicity of phosphotransferase systems for sugar uptake

· Numerous glycoside hydrolases for plant polysaccharide degradation

· Complete plantaricin biosynthesis operons for bacteriocin production

· Genes for bile salt hydrolase activity facilitating gut survival

· Adhesion-related proteins including mucus-binding proteins and sortases

The genome also contains genes encoding the glutamine-metabolizing enzyme glutaminase, which has been exploited in engineered strains for ammonia reduction in hepatic encephalopathy.

Family Characteristics

The Lactobacillaceae family comprises Gram-positive, catalase-negative, non-spore-forming rods or coccobacilli that produce lactic acid as the primary end product of carbohydrate fermentation. Members are aerotolerant anaerobes, meaning they can grow in the presence of oxygen but do not use it as an energy source. The family includes numerous probiotic species including Lacticaseibacillus rhamnosus, Limosilactobacillus reuteri, and Ligilactobacillus salivarius. Lactiplantibacillus species are distinguished by their exceptional metabolic versatility and plant-associated ecological origins.

Related Species

· Lactiplantibacillus pentosus: A closely related species with similar metabolic capabilities, often co-isolated from fermented foods and historically confused with L. plantarum.

· Lactiplantibacillus paraplantarum: Another member of the genus with distinguishing phenotypic characteristics.

· Lactiplantibacillus fabifermentans: A species associated with fermenting cocoa and coffee beans.

---

2. Therapeutic Actions

Primary Actions

· Antimicrobial (bacteriocin producer against pathogens including Listeria monocytogenes)

· Gut barrier fortifier (tight junction enhancement, mucus stimulation)

· Immunomodulator (Th1/Th2 balance, anti-inflammatory)

· Metabolic regulator (glucose homeostasis, lipid metabolism)

· Neuroactive metabolite producer (gut-brain axis modulation)

· Iron absorption enhancer (non-heme iron bioavailability)

· Ammonia reducer (via engineered strains)

Secondary Actions

· Antioxidant

· Cholesterol-lowering

· Anti-allergic (atopic dermatitis)

· Hepatoprotective

· Neuroprotective (via microbiota-gut-brain axis)

· Blood-brain barrier protector

· Anti-cancer (potential)

---

3. Bioactive Components and Their Action

Bacteriocins (Plantaricins)

Plantaricins are ribosomally synthesized antimicrobial peptides produced by L. plantarum that represent one of its most potent therapeutic weapons.

· Class IIb Two-Peptide Bacteriocins: Plantaricins EF and JK are the most well-characterized two-peptide bacteriocins, requiring synergistic action of both peptides for full antimicrobial activity. Plantaricin RX-8, a novel 13.0 kDa two-peptide bacteriocin isolated from strain RX-8, differs from plantaricin EF by four amino acid residues and exhibits a broader antimicrobial spectrum, inhibiting not only Gram-positive bacteria but also Gram-negative pathogens including Salmonella and Pseudomonas aeruginosa.

· Mechanism of Action: Plantaricins exert antimicrobial effects primarily by disrupting cell membrane integrity of target pathogens. They increase membrane permeability, cause leakage of intracellular materials, and induce proton motive force collapse, ultimately leading to bacterial cell death. This mechanism is particularly effective against Listeria monocytogenes.

· Quorum Sensing Regulation: Bacteriocin production in L. plantarum is regulated by quorum sensing mechanisms. The plantaricin A (PlnA) peptide functions as an induction factor, activating the three-component regulatory system (PlnBCD) that upregulates expression of bacteriocin structural genes. Co-cultivation with other lactic acid bacteria including Limosilactobacillus fermentum can induce enhanced bacteriocin production.

· Anti-Listeria Activity: L. plantarum strains including RX-8 and Z-5 demonstrate potent anti-Listeria monocytogenes activity. In mouse models, L. plantarum RX-8 decreased L. monocytogenes load by 2.66 lg CFU/g in colon, alleviated intestinal barrier injury, reduced inflammation via MAPK/NF-kB pathway suppression, and modulated gut microbiota by reducing harmful bacteria while promoting short-chain fatty acid-producing beneficial bacteria, resulting in a 29.01 percent increase in total SCFA levels.

· Food Preservation Applications: Bacteriocin-producing L. plantarum strains show practical utility as natural biopreservatives. Crude bacteriocin extract from strain Z-5 significantly reduced L. monocytogenes counts in milk stored at 4 degrees Celsius and 25 degrees Celsius in a concentration-dependent manner.

Short-Chain Fatty Acids (SCFAs)

L. plantarum produces SCFAs including acetate, propionate, and butyrate as byproducts of carbohydrate fermentation, contributing to systemic metabolic and immune effects.

· Gut Barrier Enhancement: SCFAs strengthen intestinal epithelial barrier function by promoting tight junction protein expression and mucus secretion.

· Immune Modulation: Through G-protein coupled receptors GPR41 and GPR43, SCFAs modulate inflammatory responses and promote regulatory T cell differentiation.

· Metabolic Signaling: Propionate influences gluconeogenesis and lipid synthesis in the liver, while acetate serves as an energy source for colonocytes.

Lactic Acid and Organic Acids

Production of lactic acid and other organic acids creates an acidic microenvironment that inhibits pathogen growth and modulates host physiology.

· Pathogen Inhibition: Lowered intestinal pH suppresses growth of acid-sensitive pathogens including many Gram-negative bacteria.

· Immune Effects: Organic acids influence dendritic cell function and may promote tolerogenic immune responses.

Surface Adhesion Proteins

L. plantarum expresses multiple mucus-binding proteins and sortase-dependent adhesins that mediate colonization of the intestinal mucosa.

· Host Interaction: Adhesion proteins facilitate direct bacterium-epithelial cell contact, enabling signaling through pattern recognition receptors.

· Competitive Exclusion: By occupying adhesion sites, L. plantarum prevents pathogen attachment to the intestinal epithelium.

Glutaminase

Native L. plantarum expresses glutaminase, an enzyme that converts L-glutamine to glutamate and ammonia. This activity has been harnessed in engineered strains for therapeutic ammonia reduction.

· Engineered Applications: In synthetic biology approaches, overexpression of native glutaminase has been used to construct L. plantarum strains capable of metabolizing L-glutamine, reducing its availability for conversion to ammonia by host glutaminase.

Engineered Ammonia Assimilation Enzymes

In the 2026 Cell study, L. plantarum WCFS1 was engineered to express heterologous enzymes enabling ammonia assimilation coupled with branched-chain amino acid biosynthesis.

· Metabolic Engineering: One engineered strain couples ammonia assimilation with BCAA biosynthesis, while another enhances L-glutamine utilization to suppress ammonia generation.

· Therapeutic Efficacy: In preclinical hepatic encephalopathy models, these engineered strains reduced systemic ammonia by up to 10-fold, restored BCAA and L-glutamine balance, and improved anxiety-like and cognitive behaviors, outperforming the clinically used therapy rifaximin while preserving gut microbiota diversity.

---

4. Clinical and Therapeutic Applications

Diabetic Macular Edema

This represents a novel and expanding frontier for L. plantarum, with a Phase 2 clinical trial initiated in 2025.

· Trial Design: A prospective, interventional, longitudinal study enrolling 36 patients with diabetic macular edema is evaluating oral L. plantarum 299v supplementation twice daily for 4 months. Patients are divided into two groups: those with mild DME not requiring anti-VEGF injections, and those requiring anti-VEGF injections as standard care.

· Primary Outcomes: The study assesses whether central macular thickness on optical coherence tomography decreases after 4 months of supplementation, visual acuity improvement at 1, 2, 3, and 4 months, and reduction in anti-VEGF injection frequency.

· Mechanistic Rationale: L. plantarum may modulate systemic inflammation underlying diabetic complications through gut barrier enhancement and immunomodulation, indirectly affecting retinal health.

Hepatic Encephalopathy and Hyperammonemia

The 2026 Cell study represents a landmark achievement in engineered probiotic therapy for complex metabolic disorders of the gut-liver-brain axis.

· Disease Context: Hepatic encephalopathy is a common complication of liver cirrhosis affecting 20 to 50 percent of patients with covert HE and 10 to 25 percent with overt HE. Current therapies including lactulose and rifaximin have limitations including side effects, cost, and risk of antibiotic resistance.

· Engineered L. plantarum Therapy: Researchers engineered L. plantarum WCFS1 strains to specifically modulate metabolites dysregulated in HE. One strain couples ammonia assimilation with BCAA biosynthesis; another enhances L-glutamine utilization to suppress ammonia generation.

· Preclinical Efficacy: In two preclinical HE models, these strains reduced systemic ammonia by up to 10-fold, restored BCAA and L-glutamine balance, and improved anxiety-like and cognitive behaviors. The engineered strains outperformed rifaximin while preserving gut microbiota diversity, which is typically disrupted by antibiotic therapy.

· Safety Profile: The engineered strains were designed in compliance with FDA guidelines for live biotherapeutic products, incorporating genomic integration of heterologous genes for stable expression and undergoing plasmid curing to eliminate the risk of introducing additional antibiotic resistance genes. The strains are cleared from the gut after dosing stops.

Atopic Dermatitis

Paraprobiotic (heat-killed) formulations of L. plantarum LRCC5195 have demonstrated significant efficacy in alleviating atopic dermatitis through gut microbiome modulation.

· Preclinical Evidence: In ovalbumin-induced AD mice, oral administration of LP5195-derived paraprobiotics for 8 weeks significantly improved AD symptoms including edema, erythema, and itching. Histological examination revealed reduced mast cell infiltration in skin tissues.

· Immune Mechanism: LP5195-P treatment decreased mRNA expression of Th2 cytokines (IL-4, IL-5, IL-13, TARC, eotaxin) in both ileum and skin tissues. Serum IgE levels were significantly reduced. Anti-inflammatory cytokine IL-10 was increased, while Th1 cytokines IL-12 and IFN-gamma were elevated, indicating rebalancing of the Th1/Th2 immune axis away from the Th2-dominant state characteristic of AD.

· Microbiome Modulation: Taxonomic analysis revealed substantially higher bacterial diversity and abundance in LP5195-P treated mice compared to controls. Metabolic analysis showed significant changes in short-chain fatty acid levels correlating with immune alterations.

· Paraprobiotic Advantage: Heat-killed formulations offer enhanced stability under extreme conditions including high temperature and pressure, are not affected by gastric or bile acids, and eliminate safety concerns associated with viable probiotics in immunocompromised populations.

Type 2 Diabetes and Metabolic Disorders

L. plantarum has demonstrated significant anti-diabetic and anti-obesity effects through multiple mechanisms involving the gut-liver axis.

· Preclinical Evidence in T2DM Mice: In high-fat diet induced T2DM mice, L. plantarum supplementation for 12 weeks significantly reduced fasting blood glucose from 11.23 to 5.87 mmol/L, comparable to healthy controls (5.87 mmol/L). Body weight gain was curtailed, and insulin sensitivity improved as measured by IPITT.

· OGTT and Glucose Tolerance: Area under the curve values in L. plantarum treated mice (28.22) were elevated versus healthy controls (22.24) but significantly decreased compared to diabetic controls (38.91), indicating improved glucose tolerance.

· Gut Microbiome Modulation: L. plantarum intervention suppressed potentially harmful bacteria including Lactobacillus johnsonii, Bacteroides acidifaciens, and Alistipes species, while enriching beneficial strains including L. acidophilus, Enterorhabdus sp. P55, and Bacteroides caecimuris.

· Bile Acid Signaling Pathway: Multi-omics analysis revealed that L. plantarum alleviates T2DM through upregulation of the bile acid secretion pathway. It increased concentrations of glycocholic acid, arachidonic acid, L-tryptophan, and palmitic acid while decreasing chenodeoxycholic acid concentration. This modulation was accompanied by upregulation of Hmgcr and Ugt1a5 mRNA expression, leading to increased levels of TGR5 (G protein-coupled bile receptor) and GLP1R (glucagon-like peptide-1 receptor).

· Liver and Pancreatic Protection: L. plantarum administration ameliorated liver and pancreatic damage in T2DM mice, with transcriptomic data indicating mitigation of liver fat accumulation through upregulation of genes including Fasn (fatty acid synthase) and Cpt1a (carnitine palmitoyltransferase 1A).

Iron Deficiency in Pregnancy

A Phase 2 clinical trial is investigating L. plantarum 299v for optimizing iron status in pregnant women at risk for iron deficiency.

· Clinical Need: Maternal iron deficiency affects approximately 18 percent of pregnant women, with iron deficiency anemia affecting 5 percent. Standard oral iron supplements are suboptimal due to gastrointestinal side effects including constipation that impair adherence.

· Mechanism for Iron Enhancement: L. plantarum 299v enhances dietary non-heme iron absorption through multiple mechanisms including reduction of intestinal pH, enhanced mucin production, and creation of an anti-inflammatory milieu. This immunomodulatory effect may reduce hepcidin production, the master regulator of systemic iron homeostasis that inhibits iron flow into circulation during inflammation.

· Trial Design: The randomized, quadruple-blind, placebo-controlled trial is enrolling 250 pregnant women at 10 to 16 weeks gestational age who are at risk for iron deficiency (hemoglobin 10.5 to 11.9 g/dL). Participants receive twice daily L. plantarum 299v or placebo until labor.

· Outcomes: The study will assess effects on maternal iron status, neonatal cord blood iron status, infant hemoglobin at birth, and the mechanisms involving gut microbiome modulation, hepcidin-ferroportin axis, and placental iron transport. Exploratory outcomes include effects on infant neurodevelopment.

Listeria monocytogenes Infection Prevention

L. plantarum strains producing anti-Listeria bacteriocins show significant protective effects against foodborne listeriosis.

· In Vitro Protection: L. plantarum RX-8 mitigated L. monocytogenes induced Caco-2 cell damage, reducing cytotoxicity by approximately 53.52 percent and significantly enhancing intestinal epithelial integrity. Bacteriocin structural gene knockout substantially diminished protective efficacy, confirming the essential role of plantaricin.

· In Vivo Efficacy: Mice pretreated with L. plantarum RX-8 showed decreased L. monocytogenes load by 2.66 lg CFU/g in colon, alleviated intestinal barrier injury through enhanced mucus secretion and tight junctions, reduced inflammation by regulating inflammatory cytokines and suppressing MAPK/NF-kB pathway activation, and modulated gut microbiota by reducing harmful bacteria while promoting SCFA-producing beneficial bacteria.

· Food Safety Applications: L. plantarum Z-5, isolated from traditional Chinese pickled cabbage, demonstrated remarkable cell surface properties, favorable safety profile, and significant tolerance to simulated gastrointestinal conditions. Its crude bacteriocin extract significantly reduced L. monocytogenes counts in milk at refrigeration and room temperatures.

Neuroinflammation and Microbiota-Gut-Brain Axis

L. plantarum WH021 has demonstrated anti-neuroinflammatory activity through regulation of the intestinal microenvironment and barrier integrity.

· Preclinical Evidence: In lipopolysaccharide-induced neuroinflammation mouse models, high-dose L. plantarum WH021 (10^9 CFU/day) for 28 days significantly improved depression-like behavior, inhibited brain inflammation and neuronal damage, and enhanced synaptic function and blood-brain barrier integrity.

· Intestinal Effects: Pathological damage and inflammation in colon tissue were effectively alleviated, and intestinal barrier function was improved.

· Mechanisms Identified: From the perspective of gut microbiota and serum metabolites, L. plantarum WH021 regulated intestinal homeostasis and increased serum metabolic levels of neuroactive components and neurotransmitter metabolites. The 5-hydroxytryptaminergic synapses, GABAergic synapses, and the arachidonic acid pathway were identified as potential mechanisms underlying its ability to alleviate neuroinflammation.

Complementary Role with Akkermansia muciniphila

Emerging evidence suggests that L. plantarum and A. muciniphila may exert complementary effects in metabolic disease management.

· Distinct but Complementary Mechanisms: L. plantarum modulates appetite-related hormones, promotes adipose tissue remodeling, reinforces intestinal barrier function, and attenuates inflammatory signaling. A. muciniphila strengthens the mucus barrier, produces beneficial metabolites, and improves immune and metabolic homeostasis.

· Ecological Interaction: Multi-omics and mechanistic studies indicate that L. plantarum-mediated metabolic remodeling may promote enrichment of A. muciniphila through cross-feeding-related processes, suggesting potential functional complementarity.

· Dual-Target Strategy: The available literature supports functional complementarity and possible additive metabolic benefits, though synergistic effects in humans remain unconfirmed. This dual-target microbial strategy represents an emerging approach for precision microbiome-based interventions in metabolic diseases.

---

5. Therapeutic Preparations and Formulations

Live Probiotic Formulation

Purpose: For metabolic disorders, antimicrobial applications, neuroinflammation, and general gut health.

· Cultivation: L. plantarum is relatively easy to cultivate compared to strict anaerobes, as it is aerotolerant and grows on standard laboratory media including MRS broth. This has facilitated its widespread use in commercial probiotic products.

· Strain Diversity: Different strains show variable properties. L. plantarum 299v is one of the most extensively studied strains with documented clinical efficacy for gastrointestinal health and iron absorption. L. plantarum WCFS1 is a well-characterized laboratory strain used for synthetic biology applications. Strains including Z-5, RX-8, WH021, and LRCC5195 each possess unique properties for specific applications.

· Formulation: L. plantarum is formulated into capsules, sachets, and food products. Its aerotolerance facilitates manufacturing and shelf stability, though refrigeration is recommended for maintaining viability in some formulations.

· Dosage: Clinical studies have used doses ranging from 10^9 to 10^11 CFU per day, typically divided into one or two doses.

Paraprobiotic (Heat-Killed) Formulation

Purpose: For immune-mediated conditions including atopic dermatitis, and for individuals where viable probiotics may be contraindicated.

· Preparation: Live L. plantarum is cultivated and then inactivated via heat treatment (pasteurization), killing the bacteria while preserving cell wall components, surface proteins, and other bioactive structures.

· Advantages: Paraprobiotics are not affected by gastric or bile acids, can be delivered to the intestines intact, and exhibit high stability under extreme conditions including high temperature and pressure. They eliminate concerns about probiotic translocation in immunocompromised individuals.

· Clinical Evidence: L. plantarum LRCC5195-derived paraprobiotics demonstrated significant efficacy in atopic dermatitis through microbiome modulation and immune rebalancing.

Engineered Live Biotherapeutic Product

Purpose: For complex metabolic disorders including hepatic encephalopathy, hyperammonemia, and other gut-liver-brain axis conditions.

· Genetic Modifications: Using synthetic biology tools, L. plantarum WCFS1 has been engineered with heterologous enzymes for ammonia assimilation coupled with BCAA biosynthesis, or with overexpression of native glutaminase for enhanced L-glutamine utilization.

· Regulatory Compliance: Strains were designed in compliance with FDA guidelines for LBPs, incorporating genomic integration of heterologous genes for stable expression and undergoing plasmid curing to eliminate antibiotic resistance genes.

· Safety Features: The engineered strains are cleared from the gut after dosing stops, preventing permanent genetic modification of the gut ecosystem.

· Preclinical Success: These strains reduced systemic ammonia by up to 10-fold in hepatic encephalopathy models, outperforming rifaximin while preserving gut microbiota diversity.

Synbiotic Formulations

Purpose: To enhance colonization and metabolic activity of L. plantarum.

· Prebiotic Substrates: L. plantarum ferments a wide range of prebiotic fibers including fructo-oligosaccharides, galacto-oligosaccharides, and inulin. Its extensive carbohydrate-active enzyme repertoire enables utilization of diverse plant-derived polysaccharides.

· Fermented Foods as Synbiotics: Traditional fermented foods naturally containing L. plantarum along with prebiotic substrates represent natural synbiotic formulations.

· Combination with Other Probiotics: L. plantarum is frequently included in multi-strain probiotic formulations alongside other Lactobacillaceae, Bifidobacterium species, and other beneficial bacteria. Co-cultivation with Limosilactobacillus fermentum has been shown to induce enhanced bacteriocin production.

---

6. In-Depth Mechanistic Profile and Clinical Significance

Bacteriocin-Mediated Pathogen Antagonism: A Multi-Layered Defense

The production of multiple bacteriocins (plantaricins) provides L. plantarum with a sophisticated antimicrobial arsenal against foodborne pathogens, particularly L. monocytogenes.

· Membrane Disruption Mechanism: Plantaricins act as membrane-active peptides, inserting into the cytoplasmic membrane of target bacteria, forming pores, and causing dissipation of the proton motive force. This leads to leakage of intracellular ions and ATP, inhibition of essential biosynthetic processes, and ultimately cell death.

· Strain-Specific Potency: Different L. plantarum strains produce distinct plantaricin variants with varying antimicrobial spectra. Plantaricin RX-8, a novel class IIb bacteriocin from strain RX-8, exhibits broader activity than typical plantaricin EF, inhibiting not only Gram-positive bacteria but also Gram-negative pathogens including Salmonella and Pseudomonas aeruginosa.

· Quorum Sensing Regulation: Bacteriocin production is not constitutive but is induced by quorum sensing. The plantaricin A peptide functions as a pheromone that, when accumulated to threshold concentration, activates the PlnBCD three-component regulatory system, leading to upregulation of bacteriocin structural genes. Co-cultivation with other LAB strains can induce enhanced production through cross-species quorum sensing.

· In Vivo Protective Efficacy: In L. monocytogenes infected mice, L. plantarum RX-8 decreased pathogen load by 2.66 log units in colon, demonstrating that bacteriocin production is functional within the complex gut ecosystem. Bacteriocin structural gene knockout substantially diminished protective efficacy, confirming the essential role of these antimicrobial peptides.

· Microbiota Modulation: Beyond direct pathogen killing, L. plantarum modulates overall gut microbiota composition, reducing harmful bacteria while promoting SCFA-producing beneficial bacteria, resulting in a 29.01 percent increase in total SCFA levels.

Gut Barrier Fortification: Protection Against Leaky Gut

L. plantarum enhances intestinal barrier integrity through multiple mechanisms, preventing translocation of pro-inflammatory bacterial products.

· Tight Junction Enhancement: L. plantarum increases expression and proper localization of tight junction proteins including occludin, claudins, and ZO-1, sealing the paracellular space between intestinal epithelial cells. In LPS-induced neuroinflammation models, L. plantarum WH021 improved intestinal barrier function, which correlated with reduced systemic inflammation and protection of the blood-brain barrier.

· Mucus Stimulation: The bacterium promotes mucus secretion from goblet cells, enhancing the physical barrier that separates luminal bacteria from the epithelial surface.

· Antimicrobial Peptide Induction: L. plantarum stimulates host production of antimicrobial peptides including defensins, further reinforcing barrier function.

· MAPK/NF-kB Pathway Suppression: In L. monocytogenes infection, L. plantarum suppresses activation of the MAPK/NF-kB inflammatory pathway, reducing production of pro-inflammatory cytokines that can compromise barrier integrity.

Immune Modulation: Balancing Th1, Th2, and Treg Responses

L. plantarum exerts sophisticated immunomodulatory effects that differ between viable and paraprobiotic formulations.

· Atopic Dermatitis Immune Rebalancing: In AD, characterized by Th2-dominant inflammation, L. plantarum LRCC5195 paraprobiotics reduced Th2 cytokines (IL-4, IL-5, IL-13, TARC, eotaxin) while increasing Th1 cytokines (IL-12, IFN-gamma) and anti-inflammatory IL-10, rebalancing the immune axis away from the allergic Th2 phenotype.

· Mast Cell Inhibition: Treatment reduced mast cell infiltration in skin tissue, with histamine release and beta-hexosaminidase activity inhibited.

· IgE Reduction: Serum IgE levels, elevated in allergic conditions, were significantly reduced by L. plantarum treatment.

· SCFA-Mediated Effects: Changes in SCFA levels correlated with immune alterations, suggesting that these bacterial metabolites mediate immunomodulatory effects through GPR41 and GPR43 receptors on immune cells.

Gut-Liver Axis: Metabolic Regulation in Type 2 Diabetes

L. plantarum alleviates T2DM through coordinated effects on gut microbiota, bile acid metabolism, and liver gene expression.

· Microbiome Restoration: In HFD-induced T2DM mice, L. plantarum suppressed potentially harmful bacteria including Bacteroides acidifaciens and Alistipes species while enriching beneficial strains including Enterorhabdus sp. P55.

· Bile Acid Signaling Modulation: Multi-omics analysis revealed upregulation of the bile acid secretion pathway as a central mechanism. L. plantarum increased glycocholic acid, arachidonic acid, L-tryptophan, and palmitic acid while decreasing chenodeoxycholic acid.

· TGR5 and GLP1R Activation: These bile acid changes led to increased levels of TGR5 (G protein-coupled bile receptor) and GLP1R (glucagon-like peptide-1 receptor). GLP-1 receptor activation enhances insulin secretion and promotes satiety, directly improving glycemic control.

· Liver Gene Expression: Transcriptomic analysis revealed upregulation of Hmgcr and Ugt1a5, genes involved in cholesterol and bile acid metabolism, along with Fasn and Cpt1a involved in fatty acid metabolism.

Gut-Brain Axis: Neuroprotection and Neuroinflammation

L. plantarum WH021 demonstrates that probiotic effects extend beyond the gut to the central nervous system through multiple interconnected mechanisms.

· Intestinal Barrier Protection: By preserving intestinal epithelial integrity, L. plantarum prevents translocation of LPS and other pro-inflammatory bacterial products that can trigger systemic and neuroinflammation.

· Systemic Inflammation Reduction: Reduced intestinal inflammation leads to lower circulating levels of inflammatory cytokines that can cross the blood-brain barrier and activate microglia.

· Blood-Brain Barrier Protection: L. plantarum WH021 directly enhanced blood-brain barrier integrity, protecting the central nervous system from peripheral inflammatory insults.

· Neuroactive Metabolite Production: The bacterium increased serum levels of neuroactive components and neurotransmitter metabolites. The 5-hydroxytryptaminergic (serotonin) and GABAergic synapses, along with the arachidonic acid pathway, were identified as potential mechanisms underlying neuroinflammation alleviation.

· Behavioral Improvements: Treated mice showed significant improvement in depression-like behavior caused by LPS-induced neuroinflammation.

Engineered Metabolic Modulation: A Platform for Complex Disorders

The 2026 Cell study establishes L. plantarum as a versatile chassis for synthetic biology applications targeting multi-organ metabolic disorders.

· Rationale for HE: Hepatic encephalopathy involves interconnected dysregulation of ammonia, BCAAs, and L-glutamine. Current therapies address single targets; an engineered probiotic addressing multiple metabolites simultaneously may be superior.

· Strain 1: Ammonia Assimilation + BCAA Production: This engineered strain couples ammonia assimilation with BCAA biosynthesis, removing toxic ammonia while producing essential amino acids depleted in HE.

· Strain 2: Enhanced L-Glutamine Utilization: This strain overexpresses native glutaminase to metabolize L-glutamine, reducing its availability for conversion to ammonia by host glutaminase, which is upregulated in cirrhotic patients.

· Superior to Rifaximin: The engineered strains outperformed rifaximin, the standard antibiotic therapy for HE, while preserving gut microbiota diversity (rifaximin causes dysbiosis).

· Safety and Clearance: The strains are cleared after dosing stops, addressing safety concerns about permanent genetic modification of the gut microbiome.

· Platform Potential: This approach can be adapted to other metabolic disorders involving dysregulated metabolite networks, representing a programmable strategy for multi-metabolite modulation.

An Integrated View of Healing with Lactiplantibacillus plantarum

· For Diabetic Macular Edema: The ongoing Phase 2 trial explores whether reducing systemic inflammation through gut microbiome modulation can decrease retinal pathology and reduce the need for anti-VEGF injections, offering a novel adjunctive strategy for this sight-threatening complication of diabetes.

· For Hepatic Encephalopathy: Engineered L. plantarum represents a paradigm shift in treating complex metabolic disorders. By simultaneously addressing multiple dysregulated metabolites (ammonia, BCAAs, L-glutamine), this approach targets the interconnected pathophysiology of HE rather than single nodes, potentially offering superior efficacy with fewer side effects.

· For Atopic Dermatitis: Paraprobiotic L. plantarum offers a safe, stable, non-viable alternative for immune modulation in allergic conditions. By rebalancing the Th1/Th2 axis, reducing IgE, and modulating the gut-skin axis, it addresses the underlying immune dysregulation of AD.

· For Type 2 Diabetes: L. plantarum provides a multi-pronged metabolic therapy targeting gut microbiome composition, bile acid signaling, and liver gene expression. Its ability to upregulate GLP-1 receptor signaling aligns with current diabetes pharmacotherapy, suggesting potential complementary use with GLP-1 receptor agonists.

· For Listeria Prevention: Bacteriocin-producing L. plantarum offers a natural, GRAS approach to preventing foodborne listeriosis, applicable both as a probiotic for at-risk populations and as a biopreservative in the food industry.

· For Pregnancy and Iron Deficiency: L. plantarum 299v offers an innovative, low-cost, safe approach to optimizing iron status in pregnancy, potentially reducing the need for poorly tolerated oral iron supplements and their associated side effects.

· For Neuroinflammation: By protecting both intestinal and blood-brain barriers and modulating the microbiota-gut-brain axis, L. plantarum offers a preventive and therapeutic strategy for neuroinflammatory conditions, potentially delaying or mitigating neurodegenerative disease progression.

---

7. Dietary Strategies to Support Endogenous L. plantarum

Purpose: To naturally increase colonization and activity of L. plantarum in the gut.

Consume Fermented Foods

Fermented foods are the primary dietary source of live L. plantarum and other beneficial lactic acid bacteria.

· Sources: Sauerkraut, kimchi, pickles (naturally fermented, not vinegar-brined), sourdough bread, fermented olives, some artisanal cheeses, and traditional fermented vegetables from various cuisines (e.g., Chinese Sichuan pickles, which yielded strains Z-5 and RX-8).

· Mechanism: These foods deliver live bacteria directly to the gastrointestinal tract. The food matrix may protect bacteria during gastric transit and provide prebiotic substrates that support colonization.

· Frequency: Regular consumption, rather than occasional intake, is recommended to maintain colonization.

Consume Prebiotic Fibers

L. plantarum requires fermentable carbohydrates for growth and metabolic activity.

· Sources: Plant-based foods rich in fermentable fibers including fruits, vegetables, legumes, and whole grains. Fructo-oligosaccharides and inulin from garlic, onions, leeks, asparagus, bananas, and chicory root are particularly beneficial.

· Mechanism: Prebiotic fibers serve as substrates for L. plantarum fermentation, producing SCFAs that benefit host health. The extensive carbohydrate-active enzyme repertoire of L. plantarum enables utilization of diverse plant polysaccharides.

Consume Polyphenol-Rich Foods

Polyphenols may support L. plantarum and other beneficial bacteria.

· Sources: Berries, grapes, pomegranates, green tea, dark chocolate, and coffee.

· Mechanisms: Polyphenols may act as prebiotic substrates, support beneficial bacteria through antioxidant effects, or inhibit competitors.

Consider Probiotic Supplements

For individuals with limited access to fermented foods or specific therapeutic goals, L. plantarum supplements are available.

· Strain Selection: Different strains have different evidence bases. L. plantarum 299v is extensively studied for gastrointestinal health and iron absorption. For specific conditions, strain-matched supplementation is recommended when available.

· Formulation: Look for products guaranteeing viability through expiration date, with appropriate colony-forming units (typically 1 to 10 billion CFU per dose).

---

8. Foods and Factors to Limit

High-Fat Diets

High-fat diets, particularly those rich in saturated fats, are associated with reduced beneficial bacteria including L. plantarum and increased risk of metabolic disease.

· Mechanisms: High-fat diets promote dysbiosis, increase gut permeability, and drive metabolic endotoxemia, creating an unfavorable environment for beneficial commensals.

· Clinical Evidence: In HFD-induced T2DM models, L. plantarum abundance is suppressed; supplementation reverses this effect.

Western Dietary Pattern

The typical Western diet high in processed foods, refined sugars, and low in fiber negatively impacts L. plantarum and overall microbiome health.

· Components: Low intake of fermented foods and prebiotic fibers fails to provide substrates that support L. plantarum metabolism.

· Microbial Effects: Western diets promote pro-inflammatory microbial profiles that may outcompete beneficial bacteria.

Antibiotic Overuse

Antibiotics, particularly those with broad-spectrum activity, can deplete L. plantarum and other beneficial bacteria.

· Susceptibility: As a Gram-positive bacterium, L. plantarum is susceptible to many common antibiotics including penicillins, macrolides, and tetracyclines.

· Recovery: Post-antibiotic recovery of L. plantarum may be supported by consumption of fermented foods or probiotic supplements.

Excessive Alcohol

Chronic alcohol consumption is associated with gut dysbiosis and reduced beneficial bacteria.

· Mechanisms: Alcohol damages the gut barrier, promotes dysbiosis, and creates conditions unfavorable for beneficial bacteria.

---

9. Therapeutic Potential in Specific Disease States: A Summary

Diabetic Macular Edema

A Phase 2 clinical trial is evaluating L. plantarum 299v supplementation for reducing central macular thickness, improving visual acuity, and decreasing anti-VEGF injection frequency in patients with DME. The trial is enrolling 36 patients with expected completion in 2027.

Hepatic Encephalopathy

Engineered L. plantarum strains reduced systemic ammonia by up to 10-fold, restored BCAA and L-glutamine balance, and improved anxiety-like and cognitive behaviors in preclinical models, outperforming rifaximin while preserving gut microbiota diversity.

Atopic Dermatitis

Paraprobiotic L. plantarum LRCC5195 alleviated AD symptoms including edema, erythema, and itching in mouse models through Th1/Th2 immune rebalancing, IgE reduction, and